ILMN vs. WAT, BRKR, MTD, BIO, AVTR, RVTY, BIO.B, PHG, ALNY, and GMAB
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Waters (WAT), Bruker (BRKR), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Koninklijke Philips (PHG), Alnylam Pharmaceuticals (ALNY), and Genmab A/S (GMAB).
Illumina (NASDAQ:ILMN) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.
Illumina has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Illumina received 647 more outperform votes than Waters when rated by MarketBeat users. Likewise, 65.73% of users gave Illumina an outperform vote while only 54.58% of users gave Waters an outperform vote.
In the previous week, Waters had 30 more articles in the media than Illumina. MarketBeat recorded 41 mentions for Waters and 11 mentions for Illumina. Illumina's average media sentiment score of 0.78 beat Waters' score of 0.18 indicating that Illumina is being referred to more favorably in the media.
Waters has a net margin of 21.72% compared to Illumina's net margin of -25.78%. Waters' return on equity of 81.30% beat Illumina's return on equity.
89.4% of Illumina shares are owned by institutional investors. Comparatively, 94.0% of Waters shares are owned by institutional investors. 0.2% of Illumina shares are owned by company insiders. Comparatively, 0.8% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Illumina presently has a consensus target price of $167.70, suggesting a potential upside of 37.61%. Waters has a consensus target price of $298.67, suggesting a potential downside of 3.24%. Given Illumina's stronger consensus rating and higher probable upside, equities analysts plainly believe Illumina is more favorable than Waters.
Waters has lower revenue, but higher earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
Summary
Waters beats Illumina on 10 of the 18 factors compared between the two stocks.
Get Illumina News Delivered to You Automatically
Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
Related Companies and Tools
